Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
1.
Chinese Traditional Patent Medicine ; (12): 2072-2076, 2017.
Article Dans Chinois | WPRIM | ID: wpr-660568

Résumé

AIM To establish an HPLC method for the simultaneous content determination of six constituents in Tibetan medicine Qishiwei Zhenzhu Pills (Croci Stigma,Dalbergiae odoriferae Lignum,Glycyrrhizae Radix et Rhizoma,etc.).METHODS The analysis of 50% methanol extract of this drug was carried out on a 30 ℃ thermostatic Inertsil(C)ODS-3 column (250 mm ×4.6 mm,5 μm),with the mobile phase comprising of 0.2% phosphoric acid-acetonitrile flowing at 0.8 mL/min in a gradient elution manner,and the detection wavelength was set at 254 nm.RESULTS Gallic acid,corilagin,agarotetrol,ellagic acid,crocin Ⅰ and crocin Ⅱ showed good linear relationships within the ranges of 1.41-42.24,0.61-18.24,0.30-9.12,0.47-14.04,0.62-18.48 and 0.32-9.45 μg/mL (R2 ≥0.999 4),whose average recoveries (RSDs) were 93.41% (1.75%),96.84% (1.75%),97.45% (0.58%),93.22% (0.56%),97.01% (1.39%) and 97.22% (1.11%),respectively.The contents of various constituents in different batches of samples from two manufactures showed some differences,especially for those of corilagin and agarotetrol.CONCLUSION We should pay attention to the unstable quality of Qishiwei Zhenzhu Pills.

2.
Chinese Traditional Patent Medicine ; (12): 2072-2076, 2017.
Article Dans Chinois | WPRIM | ID: wpr-657961

Résumé

AIM To establish an HPLC method for the simultaneous content determination of six constituents in Tibetan medicine Qishiwei Zhenzhu Pills (Croci Stigma,Dalbergiae odoriferae Lignum,Glycyrrhizae Radix et Rhizoma,etc.).METHODS The analysis of 50% methanol extract of this drug was carried out on a 30 ℃ thermostatic Inertsil(C)ODS-3 column (250 mm ×4.6 mm,5 μm),with the mobile phase comprising of 0.2% phosphoric acid-acetonitrile flowing at 0.8 mL/min in a gradient elution manner,and the detection wavelength was set at 254 nm.RESULTS Gallic acid,corilagin,agarotetrol,ellagic acid,crocin Ⅰ and crocin Ⅱ showed good linear relationships within the ranges of 1.41-42.24,0.61-18.24,0.30-9.12,0.47-14.04,0.62-18.48 and 0.32-9.45 μg/mL (R2 ≥0.999 4),whose average recoveries (RSDs) were 93.41% (1.75%),96.84% (1.75%),97.45% (0.58%),93.22% (0.56%),97.01% (1.39%) and 97.22% (1.11%),respectively.The contents of various constituents in different batches of samples from two manufactures showed some differences,especially for those of corilagin and agarotetrol.CONCLUSION We should pay attention to the unstable quality of Qishiwei Zhenzhu Pills.

3.
Chinese Journal of Oncology ; (12): 747-750, 2013.
Article Dans Chinois | WPRIM | ID: wpr-267464

Résumé

<p><b>OBJECTIVE</b>To investigate the correlation of baseline plasma D-dimer levels and clinicopathological features and tumor VEGF expression in non-small cell lung cancer(NSCLC) patients, and to evaluate the value of D-dimer in predicting survival time.</p><p><b>METHODS</b>A retrospective review of the clinicopathological data of 290 NSCLC patients confirmed pathologically in Tianjin Cancer Hospital from July 2007 to April 2009 was performed. The correlations between plasma baseline D-dimer levels and clinicopathological characteristics and progonosis were analyzed.</p><p><b>RESULTS</b>For 290 NSCLC patients with low ( ≤ 0.3 µg/ml) and high (>0.3 µg/ml) D-dimer levels, the median survival times were 54.0 months and 46.2 months, respectively (P < 0.05), and for the patients with stages I, II, IIIA, IIIB and IV NSCLC, the median survival times were 58.1, 40.6, 26.7 and 23.5 months, respectively (P < 0.05). In the operable patients (stages I, II and IIIa) with low and high D-dimer levels, the median progression-free survivals (PFS) were 35.0 and 11.0 months, respectively (P < 0.05). Furthermore, the median PFSs were 57.2 months and 19.6 months, respectively, in these operable patients without and with lymph node metastasis (P < 0.05).</p><p><b>CONCLUSIONS</b>High levels of baseline plasma D-dimer may indicate advanced disease stage, larger tumor size, lymph node metastasis and stronger tumor angiongenesis to some extent, and may be useful in prediction of survival time in NSCLC patients of different stages.</p>


Sujets)
Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Adulte d'âge moyen , Protocoles de polychimiothérapie antinéoplasique , Utilisations thérapeutiques , Carcinome pulmonaire non à petites cellules , Sang , Traitement médicamenteux , Anatomopathologie , Chirurgie générale , Cisplatine , Utilisations thérapeutiques , Survie sans rechute , Produits de dégradation de la fibrine et du fibrinogène , Métabolisme , Études de suivi , Tumeurs du poumon , Sang , Traitement médicamenteux , Anatomopathologie , Chirurgie générale , Métastase lymphatique , Stadification tumorale , Paclitaxel , Pneumonectomie , Méthodes , Modèles des risques proportionnels , Études rétrospectives , Taux de survie , Taxoïdes , Utilisations thérapeutiques , Charge tumorale , Facteur de croissance endothéliale vasculaire de type A , Métabolisme
SÉLECTION CITATIONS
Détails de la recherche